PRGO · PERRIGO COMPANY PLC

Current Thesis

Perrigo is a levered, low-multiple store-brand self-care manufacturer whose equity re-rated on one print. On 2026-08-05 the company reported Q2 net sales of $1,022.8M with core net sales down 3.1% year over year (organic down 3.5%), adjusted diluted EPS of $0.50 and reported diluted EPS of $0.63, and reaffirmed its full-year core guide of organic net sales growth of (3.0)% to +1.0% and core adjusted EPS of $2.25–$2.55 (8-K Ex-99.1, 2026-08-05). Press coverage of the release described a roughly 25% pre-market move to $13.49 on the day. The shares are up 30.5% over three months into the 2026-09-04 close of $14.92, still 29.5% under the 52-week high of $21.17.

The narrative leg being bought is a balance-sheet story wearing a consumer-staples label: $3.3B of total debt against $400M of cash and a $2.07B market cap (stockanalysis.com, 2026-09-05), so each turn of portfolio pruning and cost-out lands on a small equity base. The Dermacosmetics sale closed with roughly $359M of proceeds substantially applied to debt reduction, and management said on 2026-08-05 that strategic reviews of the Infant Formula and Oral Care businesses are continuing. The narrative is accelerating but on a narrow bid — the re-rate began with the 2026-08-05 print, the only third-party attention in the 30 days since was a Benzinga high-yield healthcare screen on 2026-08-25, and public.com listed just three analysts covering the name as of 2026-09-02.

Bullish and bearish views on PERRIGO COMPANY PLC

The model's bull view on PERRIGO COMPANY PLC (PRGO), in brief: The guide survived a bad top line. Core net sales fell 3.1% in Q2 2026 and the full-year core adjusted EPS range of $2.25–$2.55 was still reaffirmed on 2026-08-05, with adjusted gross margin of 35.6% versus 30.7% reported. The equity had been priced for a cut that did not come.… The bear view: The demand line is still negative. Q2 core net sales down 3.1% (organic down 3.5%) was attributed to soft consumer self-care categories, retailer inventory reductions and a slow seasonal start. Nothing in the 2026-08-05 release shows the category inflecting; the guide is… Both cases follow in full.

Bull Case

• The guide survived a bad top line. Core net sales fell 3.1% in Q2 2026 and the full-year core adjusted EPS range of $2.25–$2.55 was still reaffirmed on 2026-08-05, with adjusted gross margin of 35.6% versus 30.7% reported. The equity had been priced for a cut that did not come.
• Deleveraging is being funded by asset sales, not equity. The Dermacosmetics divestiture generated approximately $359M, substantially deployed against the $3.3B debt load (8-K Ex-99.1, 2026-08-05). Two more reviews — Infant Formula and Oral Care — were confirmed as open at the same date.
• Cost program with a stated number. Coverage of the 2026-08-05 call cited an Operational Enhancement Program targeting $80M–$100M of savings by 2027, against a full-year adjusted EPS range whose midpoint sits near $2.40.
• Cash generation turned within the quarter. Operating cash flow was $83M in Q2 against negative $31M for the first six months of 2026 (8-K Ex-99.1, 2026-08-05) — the half-year figure is the one that has to reverse.
• Sell-side is not crowded in. Canaccord Genuity carried a Buy rating as of 2026-08-06; stockanalysis.com showed a consensus target of $16.50 on 2026-09-05 and public.com a $19.33 average across three analysts on 2026-09-02. Thin coverage means single notes move the consensus.

Bear Case

• The demand line is still negative. Q2 core net sales down 3.1% (organic down 3.5%) was attributed to soft consumer self-care categories, retailer inventory reductions and a slow seasonal start. Nothing in the 2026-08-05 release shows the category inflecting; the guide is explicitly weighted to the second half.
• GAAP earnings are deeply negative. Trailing-twelve-month EPS of -$12.49 on a -$1.73B net loss (stockanalysis.com, 2026-09-05) reflects prior write-downs — the equity screens as a loss-maker on reported numbers.
• Leverage dominates the equity. $3.3B of debt sits above a $2.07B market cap. A 2027 macro or category disappointment is absorbed by equity holders first.
• The dividend is a claim on cash the company did not generate in H1. The declared annual rate is $1.16 per share, a 7.78% yield at recent prices, with an ex-dividend date of 2026-08-28 (stockanalysis.com, 2026-09-05), against negative $31M of six-month operating cash flow.
• Leadership is temporary. Patrick Lockwood-Taylor resigned as CEO in June 2026 over personal misconduct; board member Albert Manzone holds the President and CEO roles on an interim footing. A permanent hire can rebase the plan and the charges that come with it.
• The 2026-08-05 gap is the whole structure. Everything above roughly $13 was created in a single session; there is no multi-month shelf underneath it.

Setup & Price Structure

The 2026-09-04 close of $14.92 sits 29.5% below the 52-week high of $21.17, with RSI(14) at 75.7 — an extended momentum reading on a name that has round-tripped nothing of its 2025 decline. The move is gap-driven: the 2026-08-05 print produced a roughly 25% jump to $13.49 pre-market, and price has continued higher in a low-coverage tape rather than backfilling.

Positioning observables, stated as observables: RSI(14) of 75.7 on 2026-09-04; a three-month price change of +30.5%; a stockanalysis.com consensus target of $16.50 on 2026-09-05, only modestly above the last close, which means further upside requires target revisions rather than gap-closing; retail-facing coverage clustering on the yield rather than the operations (Benzinga, 2026-08-25); the ex-dividend date of 2026-08-28 already passed, removing the yield-capture bid until the next declaration; and no company earnings date inside the next 30 days. There is no reported insider selling or equity issuance in the filings available for this window — absence of evidence, not evidence of absence.

Structural reference points: the 2026-08-05 gap zone near $13.00–$13.50 is the first real support built by volume; below that, the pre-print range from July 2026 is open air. The $16.50 consensus zone is the nearest area where a mechanical seller (target-reached) meets the tape.

Catalyst Calendar (next 30 days)

• 2026-09-10 — Interim President and CEO Albert Manzone and CFO Eduardo Bezerra participate in investor meetings at the Barclays Global Consumer Conference (announced 2026-08-27). The only dated company appearance in the window; the venue where an infant-formula or oral-care review update would most plausibly be framed.
• ~2026-11-05 (est.) — Q3 2026 results. Not in the 30-day window, but it is the print that tests the second-half-weighted $2.25–$2.55 core EPS guide.

Elapsed catalysts

• Undated, live — Outcome of the Infant Formula and Oral Care strategic reviews, confirmed as continuing on 2026-08-05. These land by press release, not on a schedule. (passed 32d ago)

What Would Change Our Mind

The structure that breaks first is the 2026-08-05 earnings gap: it is the only volume shelf under this move, and losing it would return the shares to the pre-print range with the reaffirmed guide already in the price. A weekly close below $13.00 marks that failure and ends the re-rating leg.

The second break is informational rather than technical. If the 2026-09-10 Barclays appearance passes with no update on the infant-formula or oral-care reviews and no upward revision to the $2.25–$2.55 core guide, the name has no company-dated catalyst until roughly early November, with RSI(14) already at 75.7 — a narrative that has gone from accelerating to well known without a widening bid.

The third is fundamental and dated: a Q3 print showing core net sales still down year over year while the full-year core adjusted EPS range is trimmed below $2.25 would remove the reaffirmation that caused the August move. Equally, any change to the $1.16 declared annual dividend rate would tell a different story about the cash the debt load allows.

Conversely, a disclosed sale agreement for Infant Formula or Oral Care with proceeds directed to the $3.3B debt balance would strengthen the case rather than break it, and would make the $16.50 consensus zone a way-station rather than a ceiling.

Correlation Notes

No current theme cluster carries this name; it trades as a single-name situation and the thesis does not lean on a group move. Directionally it tracks the consumer-health complex (Kenvue, Haleon, Church & Dwight) on category demand and retailer destocking commentary, and it is exposed to the shelf-space decisions of a handful of large US and European retailers through the store-brand model. The infant-formula review ties one leg of the story to a category with concentrated branded competition and regulatory scrutiny.

Second-order: with $3.3B of debt against a $2.07B market cap and a 7.78% declared yield, the equity behaves partly like a levered credit — sensitive to refinancing conditions and to rate-driven rotation between yield vehicles, which is why a yield-screen article (Benzinga, 2026-08-25) rather than an operational note was the marginal coverage in the last month. Idiosyncratic drivers — the CEO search, the two divestiture reviews — are uncorrelated with anything else in a self-care basket and are where most of the variance sits.